home > ebr > autumn 2012 > mindful medical monitoring


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO®▼ (Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release

BEERSE, BELGIUM, 27 March 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced further findings for SPRAVATO® (esketamine nasal spray [NS]) from the ESCAPE-TRD study. Data show that adults with treatment-resistant major depressive disorder (TRD) treated with esketamine NS achieved significantly* higher remission rates from Week 6 and response rates as early as Day 15 in the study, and at every subsequent time-point through Week 32, compared to adults treated with quetiapine extended-release (XR), when both were dosed as per their respective labels and used in combination with a continuing selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI).1 The findings were presented at the 31st European Congress of Psychiatry (EPA 2023) taking place from March 25 to March 28 in Paris, France, following earlier top line data from the study presented at the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Congress last year.2 *Tested at a two-sided 0.05 significance level without adjustment for multiple testing.1 2 CP-374947 March 2023
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement